Departments of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Department of, Radiology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Dig Endosc. 2021 Jul;33(5):840-848. doi: 10.1111/den.13871. Epub 2020 Nov 24.
Non-surgical methods have high success rates for treating benign biliary strictures (BBSs), but treatment of proximal strictures is difficult. Recent studies have reported that fully covered self-expandable metal stents (FCSEMSs) are useful for treating refractory BBSs. We investigated the efficacy of a short and removable FCSEMS with an anti-migration design for treatment of proximal BBSs.
Fully covered self-expandable metal stents were inserted endoscopically in patients with BBSs after living donor liver transplantation (LDLT). Each FCSEMS was initially maintained for 3 months and subsequently exchanged every 3 months until the stricture resolved. Adverse events and stricture recurrence after FCSEMS removal were assessed during follow-up.
A total of 63 patients with a median age of 57 years were enrolled in this study; 50 were male. The most common underlying disease was hepatocellular carcinoma and the previous operation was LDLT. The mean duration from surgery to diagnosis of stricture was 8.5 months, and the mean stent indwelling time was 4.2 months. The technical success and stricture resolution rate were 100%. The recurrence rate was 23.8% and the adverse event rate was 12.7%. All stents were removable, and asymptomatic stent migration was observed in four patients (6.4%).
The newly designed FCSEMS is effective in the treatment of proximal BBSs after LDLT.
非手术方法治疗良性胆道狭窄(BBS)的成功率较高,但近端狭窄的治疗较为困难。最近的研究报道,全覆膜自膨式金属支架(FCSEMS)对于治疗难治性 BBS 是有用的。我们研究了一种具有抗迁移设计的短而可移除的 FCSEMS 治疗近端 BBS 的疗效。
在活体供肝移植(LDLT)后,经内镜插入 BBS 患者的 FCSEMS。每个 FCSEMS 最初维持 3 个月,然后每 3 个月更换一次,直到狭窄缓解。在随访期间评估 FCSEMS 移除后的不良事件和狭窄复发情况。
共纳入 63 例中位年龄为 57 岁的患者;其中 50 例为男性。最常见的基础疾病是肝细胞癌,先前的手术是 LDLT。从手术到诊断狭窄的平均时间为 8.5 个月,支架留置时间的平均为 4.2 个月。技术成功率和狭窄缓解率均为 100%。复发率为 23.8%,不良事件发生率为 12.7%。所有支架均可移除,4 例(6.4%)患者出现无症状支架迁移。
新设计的 FCSEMS 对于 LDLT 后近端 BBS 的治疗是有效的。